These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7431220)

  • 1. Evaluation of the absorption from some commercial enteric-release theophylline products.
    Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the absorption from some commercial sustained-release theophylline products.
    Upton RA; Thiercelin JF; Guentert TW; Sansom L; Powell JR; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):131-49. PubMed ID: 7431219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption of theophylline from enteric coated and sustained release formulations in fasted and non-fasted subjects.
    Osman MA; Patel RB; Irwin DS; Welling PG
    Biopharm Drug Dispos; 1983; 4(1):63-72. PubMed ID: 6839003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption of theophylline from conventional and sustained-release tablets.
    Fagerström PO; Mellstrand T; Svedmyr N
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relation of product formulation to absorption of oral theophylline.
    Weinberger M; Hendeles L; Bighley L
    N Engl J Med; 1978 Oct; 299(16):852-7. PubMed ID: 692577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability.
    Rivera-Calimlim L; Calimlim JF; Liang R; Lasagna L; Diamond GL
    J Asthma; 1986; 23(3):113-22. PubMed ID: 3528119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption of theophylline from conventional and sustained-release tablets.
    Mellstrand T; Svedmyr N; Fagerström PO
    Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.
    Horai Y; Ishizaki T; Sasaki T; Chiba K; Suganuma T; Echizen H; Ohnishi A
    Eur J Clin Pharmacol; 1983; 24(1):79-87. PubMed ID: 6832206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food on the bioavailability and pattern of release of a sustained-release theophylline tablet.
    Leeds NH; Gal P; Purohit AA; Walter JB
    J Clin Pharmacol; 1982 Apr; 22(4):196-200. PubMed ID: 7096605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissolution studies of some sustained-release theophylline dosage forms.
    Simons KJ; Simons FE; Plett KD; Scerbo C
    J Pharm Sci; 1984 Jul; 73(7):939-42. PubMed ID: 6470957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative bioavailability of a microcrystalline theophylline tablet and uncoated aminophylline tablets.
    Sansom LN; Milne RW; Cooper D
    Eur J Clin Pharmacol; 1979; 16(6):417-21. PubMed ID: 583332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet.
    Lagas M; Jonkman JH
    Eur J Clin Pharmacol; 1983; 24(6):761-7. PubMed ID: 6884413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets.
    Jonkman JH; van der Boon WJ; Schoenmaker R; Holtkamp A; Thürkow-Luikens AJ
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):506-10. PubMed ID: 6500770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the absorption from 15 commercial theophylline products indicating deficiencies in currently applied bioavailability criteria.
    Upton RA; Sansom L; Guentert TW; Powell JR; Thiercelin JF; Shah VP; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Jun; 8(3):229-42. PubMed ID: 7420268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preparation and evaluation of press-coated aminophylline tablet using crystalline cellulose and polyethylene glycol in the outer shell for timed-release dosage forms].
    Watanabe Y; Mukai B; Kawamura K; Ishikawa T; Namiki M; Utoguchi N; Fujii M
    Yakugaku Zasshi; 2002 Feb; 122(2):157-62. PubMed ID: 11857956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D; Molz KH; Staib AH; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissolution and bioavailability studies of whole and halved sustained-release theophylline tablets.
    Simons KJ; Frith EM; Simons FE
    J Pharm Sci; 1982 May; 71(5):505-11. PubMed ID: 7097493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.
    Hendeles L; Iafrate RP; Weinberger M
    Clin Pharmacokinet; 1984; 9(2):95-135. PubMed ID: 6370542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multiple-dose study of sustained-release theophylline and aminophylline.
    Meyer MC; Straughn AB; Lieberman P
    Chest; 1980 Aug; 78(2):300-3. PubMed ID: 7398417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.